Literature DB >> 28612362

The economic burden of neonatal abstinence syndrome in the United States.

Tammy E Corr1, Christopher S Hollenbeak2.   

Abstract

BACKGROUND AND AIMS: While hospital charges related to neonatal abstinence syndrome (NAS) have increased recently, there are no data available regarding costs. Therefore, we sought to describe the NAS population and compare with the non-NAS population, determine the incidence of NAS in the United States and estimate the total annual costs and hospital days of NAS admissions, and estimate the incremental costs and length of stay of an NAS admission compared with a non-NAS admission.
DESIGN: Retrospective, observational study. Data were obtained from the Kids' Inpatient Database (2003-12). Survey-weighting was used to obtain national counts of NAS births. The incremental burden of costs and length of stay were estimated for NAS admissions and compared to non-NAS admissions.
SETTING: United States hospitals from states participating in the Kids' Inpatient Database (KID), a nationally representative sample of all-payer in-patient pediatric discharges. PARTICIPANTS: Infants with a diagnosis of NAS (27 943) were identified from the KID using ICD-9-CM codes and compared with non-NAS infants (3 783 629). MEASUREMENTS: Primary outcome measures were provider costs and length of stay for NAS and non-NAS admissions. Costs were calculated using cost-to-charge ratios and were adjusted for inflation to 2014 US dollars.
FINDINGS: Between 2003 and 2012, NAS admissions increased more than fourfold, resulting in a surge in annual costs from US$61 million and 67 869 hospital days in 2003 to nearly US$316 million and 291 168 hospital days in 2012. For an infant affected by NAS, the hospital stay was nearly 3.5 times as long (16.57 hospital days compared with 4.98 for a non-NAS patient, P < 0.001) and the costs more than three times greater (US$16 893 compared to US$5610 for a non-affected infant, P < 0.001).
CONCLUSION: The incidence of neonatal abstinence syndrome is increasing in the United States, and carries an enormous burden in terms of hospital days and costs. The number of US hospital admissions involving neonatal abstinence syndrome increased more than fourfold between the years 2003 and 2012. In 2012, neonatal abstinence syndrome cost nearly $316 million in the United States.
© 2017 Society for the Study of Addiction.

Entities:  

Keywords:  Buprenorphine; finnegan scores; maternal substance abuse; methadone; neonatal abstinence syndrome; opioid abuse; prescription opioids; withdrawal

Mesh:

Year:  2017        PMID: 28612362     DOI: 10.1111/add.13842

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  24 in total

Review 1.  The United States opioid epidemic.

Authors:  Jennifer Lyden; Ingrid A Binswanger
Journal:  Semin Perinatol       Date:  2019-01-14       Impact factor: 3.300

2.  Subclinical and Overt Newborn Opioid Exposure: Prevalence and First-Year Healthcare Utilization.

Authors:  Zana Percy; Cole Brokamp; Jennifer M McAllister; Patrick Ryan; Scott L Wexelblatt; Eric S Hall
Journal:  J Pediatr       Date:  2020-05-15       Impact factor: 4.406

3.  Incidence and Costs of Neonatal Abstinence Syndrome Among Infants With Medicaid: 2004-2014.

Authors:  Tyler N A Winkelman; Nicole Villapiano; Katy B Kozhimannil; Matthew M Davis; Stephen W Patrick
Journal:  Pediatrics       Date:  2018-04       Impact factor: 7.124

4.  Neonatal Abstinence Syndrome Incidence and Health Care Costs in the United States, 2016.

Authors:  Andrea E Strahan; Gery P Guy; Michele Bohm; Meghan Frey; Jean Y Ko
Journal:  JAMA Pediatr       Date:  2020-02-01       Impact factor: 16.193

Review 5.  Risk Factors Associated with the Occurrence of Neonatal Opioid Withdrawal Syndrome: A Review.

Authors:  Erin Kelty; David B Preen
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

6.  Comparison of Safety and Efficacy of Methadone vs Morphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Clinical Trial.

Authors:  Jonathan M Davis; Jeffrey Shenberger; Norma Terrin; Janis L Breeze; Mark Hudak; Elisha M Wachman; Peter Marro; Erica L Oliveira; Karen Harvey-Wilkes; Adam Czynski; Barbara Engelhardt; Karen D'Apolito; Debra Bogen; Barry Lester
Journal:  JAMA Pediatr       Date:  2018-08-01       Impact factor: 16.193

7.  Capturing the statewide incidence of neonatal abstinence syndrome in real time: the West Virginia experience.

Authors:  Amna Umer; Sean Loudin; Stefan Maxwell; Christa Lilly; Meagan E Stabler; Lesley Cottrell; Candice Hamilton; Janine Breyel; Christina Mullins; Collin John
Journal:  Pediatr Res       Date:  2018-10-04       Impact factor: 3.756

8.  Infants in Drug Withdrawal: A National Description of Nurse Workload, Infant Acuity, and Parental Needs.

Authors:  Jessica G Smith; Jeannette A Rogowski; Kathryn M Schoenauer; Eileen T Lake
Journal:  J Perinat Neonatal Nurs       Date:  2018 Jan/Mar       Impact factor: 1.638

9.  Well-Child Care Adherence After Intrauterine Opioid Exposure.

Authors:  Neera K Goyal; Jessica F Rohde; Vanessa Short; Stephen W Patrick; Diane Abatemarco; Esther K Chung
Journal:  Pediatrics       Date:  2020-01-02       Impact factor: 7.124

Review 10.  Neonatal abstinence syndrome: an update.

Authors:  Lauren A Sanlorenzo; Ann R Stark; Stephen W Patrick
Journal:  Curr Opin Pediatr       Date:  2018-04       Impact factor: 2.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.